ERCC1 and Thymidylate Synthase mRNA Levels Predict Survival for Colorectal Cancer Patients Receiving Combination Oxaliplatin and Fluorouracil Chemotherapy
Journal of Clinical Oncology2001Vol. 19(23), pp. 4298–4304
Citations Over TimeTop 10% of 2001 papers
Yoshinori Shirota, Jan Stoehlmacher, Jan Brabender, Yi-Ping Xiong, Hiroyuki Uetake, Kathleen D. Danenberg, Susan Groshen, Denise D. Tsao‐Wei, Peter V. Danenberg, Heinz‐Josef Lenz
Abstract
These data suggest that intratumoral ERCC1 mRNA and TS mRNA expression levels are independent predictive markers of survival for 5-FU and oxaliplatin combination chemotherapy in 5-FU-resistant metastatic colorectal cancer. Precise definition of the best TS cut point will require further analysis in a large, prospective study.
Related Papers
- → Phase I study of weekly oxaliplatin plus irinotecan in previously treated patients with metastatic colorectal cancer(2002)18 cited
- → The Role of 5-Fluorouracil (5-FU) Reintroduction with Irinotecan or Oxaliplatin in Truly 5-FU-Refractory Advanced Colorectal Cancer Patients(2005)3 cited
- → ERCC1 and Thymidylate Synthase as Prognostic Biomarkers in Malignant Mesothelioma(2015)
- → Increased response of oxaliplatin or irinotecan on in vitro chemosensitivity to 5-fluorouracil in patients with colorectal cancer(2014)
- → ERCC1, as Prognostic and Predictive Marker in Metastatic Colorectal Cancer Patients Treated with Oxaliplatin based Chemotherapy(2016)